Application of an Open-Source Modular Framework for Pharmacokinetic, Pharmacodynamic, and Safety Simulations to Anti-Tuberculosis Drugs
Abstract
Tuberculosis (TB) treatment requires long-term multidrug regimens where dosing, efficacy, and safety optimization remain challenging. This tutorial establishes an integrated, open-source, modular framework connecting high-throughput PBPK (HT-PBPK) simulations, mechanistic PBPK models, pharmacodynamic endpoints, and safety predictions for anti-TB drugs. Using the Open Systems Pharmacology Suite and ESQhtpbpk (R package), physicochemical parameters were obtained from literature, with QSAR-predicted values supplementing missing experimental data to generate generic PBPK models. Mechanistic models were parameterized for moxidectin, isoniazid, moxifloxacin, bedaquiline, and rifampicin. A quantitative TB disease model of host-pathogen dynamics and PK-PD interactions was integrated to assess efficacy. A cardiac electrophysiology model incorporating ion channel inhibition data was coupled with PBPK predictions for moxifloxacin and bedaquiline. The HT-PBPK framework automated virtual studies across compounds and dosing regimens. Mechanistic models reproduced systemic and local disposition within two-fold of the observed data. The TB disease model predicted treatment response across exposure scenarios. The cardiac module captured the dose-QTc relationship for moxifloxacin and identified metabolite-driven QTc prolongation with bedaquiline, consistent with clinical observations. This open-source, modular framework spans compound screening, mechanistic PK, efficacy, and cardiotoxicity,…
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.